Curaleaf's Hostile Takeover Attempt of Aurora Cannabis Is Hitting Turbulence. Here's What Investors Should Watch.

Curaleaf's $4-per-share hostile takeover bid for Aurora Cannabis (ACB), launched in August 2026 and rejected by Aurora's board as undervalued, faces mounting complications as the December 1 tender offer deadline approaches. Curaleaf has escalated tactics by attempting to block Aurora's access to capital markets through restrictions on equity raises, adding friction to an already contentious acquisition attempt.

The hostility between the two cannabis companies raises integration risk if Curaleaf's offer succeeds. Aurora shareholders now face a binary decision: tender shares at the $4 offer price or hold for a potential higher bid or standalone upside. The board's rejection signals management believes the company is worth more than Curaleaf's proposal, though no competing bid has emerged publicly.

The attempted capital-raise blockade adds urgency for Aurora, potentially limiting its ability to fund operations or pursue alternatives while the tender window remains open. Curaleaf's aggressive posture suggests confidence in the offer's adequacy despite Aurora's resistance.